EP1549633A1 - Nicotine-containing, controlled release composition and method - Google Patents

Nicotine-containing, controlled release composition and method

Info

Publication number
EP1549633A1
EP1549633A1 EP03724037A EP03724037A EP1549633A1 EP 1549633 A1 EP1549633 A1 EP 1549633A1 EP 03724037 A EP03724037 A EP 03724037A EP 03724037 A EP03724037 A EP 03724037A EP 1549633 A1 EP1549633 A1 EP 1549633A1
Authority
EP
European Patent Office
Prior art keywords
nicotine
cation exchange
exchange resin
organic polyol
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03724037A
Other languages
German (de)
French (fr)
Other versions
EP1549633A4 (en
EP1549633B1 (en
Inventor
John A. Walling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambrex Charles City Inc
Original Assignee
Cambrex Charles City Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22602397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1549633(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambrex Charles City Inc filed Critical Cambrex Charles City Inc
Priority to SI200331402T priority Critical patent/SI1549633T1/en
Publication of EP1549633A1 publication Critical patent/EP1549633A1/en
Publication of EP1549633A4 publication Critical patent/EP1549633A4/en
Application granted granted Critical
Publication of EP1549633B1 publication Critical patent/EP1549633B1/en
Priority to CY20081101133T priority patent/CY1108411T1/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Definitions

  • This invention relates to a method for producing a nicotine-containing composition having a controlled release rate of nicotine. More particularly, this invention relates to a process for producing product comprising nicotine and a cation exchange resin, such product having a nicotine release rate of at least 70% over a 10 minute period.
  • Nicotine is a well know, highly characterized alkaloid that can be isolated from the dried leaves of Nicotiana tabacum. Its numerous commercial uses include utilities such as a fumigant, an insecticide and the like. It is therapeutically valuable in the treatment of the smoking withdrawal syndrome. This treatment is based on the fact that the administration of nicotine into the body has been readily accomplished by the method of smoking, e.g., from cigarettes, pipes or cigars. The smoker experiences a satisfactory sensation from such administration. However, smoking may be associated with health hazards not necessarily associated with nicotine administration itself.
  • non-smoking methods have been devised to administer nicotine to the body.
  • These include nicotine-containing chewing gums, nicotine-impregnated dermal patches, nicotine inhalers and the like.
  • a variety of patents have disclosed such products.
  • U.S. Patent No. 4,692,462 discloses a transdermal drug delivery system having a drug reservoir composed, in part, of an ion exchange resin.
  • the drug reservoir also contains water and therefore has a disadvantageous ⁇ short shelf life.
  • WO 94/08572 is similar to the above-identified '462 patent but has a nonaqueous component, which increases the shelf life.
  • U.S Patent 3,901,248 discloses a chewable smoking substitute composition that comprises a chewing gum base and nicotine in combination with certain saliva-insoluble cation exchange resins. When such composition is chewed, nicotine is released in small and reduced amounts into the mouth, within the first few minutes of chewing. The composition is marginally effective in inducing the pleasurable sensation of smoking that is typically desired from those engaged in the therapy that incorporates such chewing gum.
  • the present invention relates to a nicotine product having a nicotine release rate of not less than 70% over a 10 minute period as well as a process to produce such product
  • a product is produced by a process comprising the steps of:
  • a cation exchange resin selected from the group consisting of (i) - a methacrylic, weakly acidic type of resin containing carboxylic functional groups (ii) - polystyrene, strongly acidic type of resin contaimng sulfonic functional groups and (iii) - polystyrene, intermediate acidic type of resin containing phosphonic functional groups thereby forming a cation exchange resin mixture having some of its ion exchange sites partially blocked with said polyol;
  • step (c) admixing with said mixture of step (b) an aqueous solution of nicotine to form a nicotinecoated cation exchange resin admixture;
  • the nicotine composition having a nicotine release rate of not less than 70% over a ten minute period results.
  • a process, product from such process and composition resulting from this process are disclosed.
  • the composition is one that contains nicotine.
  • the nicotine in the composition herein has a release rate of not less than 70% over a period of 10 minutes. The method by which such release rate is determined is described in more detail in the U.S.P. Official Monograph, Volume 25, pages 1225 and 1226, incorporated herein by reference.
  • the product produced by the process according to the present invention contains, in addition to the above-disclosed nicotine, a cation exchange resin and an organic polyol.
  • any nonionic pharmaceutical grade cationic ion-exchange resin used to bind anionic molecules at the ion exchange sites may be employed in this invention.
  • cationic materials are: the those bearing a carboxylic acid group, such as a weakly acidic type of resin containing carboxylic functional groups (these resins are typically derived from polymers or copolymers of methacrylic acid or polymethacrylic acid); the strongly acidic type of resins containing sulfonic functional groups (these resins are typically derived from polymers of styrene or copolymers of styrene and divinylbenzene); or the intermediate acidic type of resins containing phosphonic acid functional groups (these resins are typically derived from polymers of styrene or copolymers of styrene and divinylbenzene).
  • Cationic ion exchange resins are well know in the art and the present invention encompasses all of these.
  • Representative cation exchange resins of use in accordance with the present invention are disclosed in U.S. Patent No. 3,901,258 incorporated herein by reference.
  • the preferred cation exchange resins are those known in the art as the Amberlite® resins and include, for example, Amberlite® IR-20, Amberlite® IRP-69, Amberlite® IRP-64, Amberlite® IRP-58, Amberlite® IRC-50, Amberlite® IRP-69, etc.
  • the product in accordance with the present invention also contains as organic polyol.
  • the organic polyol is a non-toxic C 2 to C ⁇ 2 linear or branched hydrocarbon having at least 2 hydroxy groups or a non-toxic C 5 to C 12 cyclic or heterocyclic hydrocarbon having at least 2 hydroxy groups.
  • the former compounds are illustrated by the polyhydric alcohols such as 1,3- carbohydrates such as glucose, sucrose, etc.
  • the organic polyol In carrying the process in accordance with the present invention, it is necessary to combine the organic polyol with the cation exchange resin to form a mixture (slurry). Any form of mixing is acceptable. However, it is important that the ratio of cation exchange resin to organic polyol is from about 1:1 to about 5:1. Preferably, the ratio of cation exchange resin to organic polyol is from about 2:1 to about 4:1, most preferably about 2.5:1.
  • an aqueous solution of nicotine is admixed an aqueous solution of nicotine.
  • concentration of nicotine in said aqueous solution of nicotine is from about 5% by weight to about 40% by weight, preferably about 10% to about 30% by weight, most preferably about 15% by weight.
  • weight percent of nicotine in water as used in the present invention is somewhat arbitrary, since water is already present in the process. As set forth herein for this process, such nicotine concentration can be from about 5% to about 40% by weight, but it could also be up to about 50% or higher.
  • the ratio of cation exchange resin to nicotine is from about 2:1 to about 10:1.
  • the ratio of cation exchange resin to nicotine is from about 3:1 to about 6:1, most preferably, about 4:1.
  • the admixture which is a water slurry of the cation exchange resin incorporating nicotine and the organic polyol is then dried to remove the water.
  • drying can be carried out by any conventional means, i.e., dried over a purge of nitrogen, dried under vacuum, etc..
  • drying the admixture at temperatures in excess of 75 - 80° C cause the disadvantageous loss of nicotine and should be avoided.
  • the dried admixture is typically sieved to a substantially uniform particle size before being used.
  • Nicotine/Resin Process A 1 liter 3-neck, jacketed round bottom flask fitted with external heating/cooling, mechanical agitation and a nitrogen gas inlet is charged with Amberlite® IRP-64 resin (61.0 grams) and a solution of the polyol (24.0 grams) and water (146.4 grams). The mixture is agitated for at least 2 hours at 20 - 25 °C under a nitrogen atmosphere. A solution of nicotine (15.0 grams) and water (36.6 grams) is then added to the mixture and agitation is continued for 1 additional hour.
  • the flask is reconfigured for vacuum distillation. Water is distilled from the reaction mixture at a temperature not to exceed 70°C and at ⁇ 25" of vacuum. The process is halted when water stops being collected as distillate. At that point, the reaction mixture (the residue remaining in the flask) is a solidified mass. This solid material is transferred to a drying dish and further dried in a vacuum at 50 - 60°C with nitrogen purge. The mixture is considered dry when a Karl Fisher analysis shows the water content in the solid mass to be ⁇ 5%.
  • a number of polyols illustrative of the present invention were individually processed in the above Nicotine/Resin Process.
  • the dried mixtures containing these different polyols were analyzed to determine nicotine concentration and release rate of nicotine according to the procedure set forth in the U.S.P. Official Monograph, Volume 25, pages 1225 and 1226.
  • the results for the illustrative polyols are reported below in the Table 1.
  • the release rate for the No Polyol is also confirmed by this precision study. It always gives a value of ⁇ 70%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A nicotine product having a nicotine release rate of not less than 70% over a 10 minute period as well as a process to produce such product. Such product is produced by a process comprising the steps of(a) preparing an aqueous solution of an organic polyol;(b) mixing said aqueous solution of the organic polyol with a cation exchange resin selected from the group consisting of (i)-a methacrylic, weakly acidic type of resin containing carboxylic functional groups (ii)-polystyrene, strongly acidic type of resin containing sulfonic functional groups and (iii)-polystyrene, intermediate acidic type of resin containing phosphonic functional groups thereby forming a cation exchange resin mixture having some of its ion exchange sites partially blocked with said polyol;(c) admixing with said mixture of step (b) an aqueous solution of nicotine to form a nicotine-coated cation exchange resin admixture; and(d) removing water from said admixture.The nicotine composition having a nicotine release rate of not less than 70% over a 10 minute period results.

Description

Nicotine-Containing, Controlled Release Composition and Method
Field of Invention
This invention relates to a method for producing a nicotine-containing composition having a controlled release rate of nicotine. More particularly, this invention relates to a process for producing product comprising nicotine and a cation exchange resin, such product having a nicotine release rate of at least 70% over a 10 minute period.
Background of the Invention
Nicotine is a well know, highly characterized alkaloid that can be isolated from the dried leaves of Nicotiana tabacum. Its numerous commercial uses include utilities such as a fumigant, an insecticide and the like. It is therapeutically valuable in the treatment of the smoking withdrawal syndrome. This treatment is based on the fact that the administration of nicotine into the body has been readily accomplished by the method of smoking, e.g., from cigarettes, pipes or cigars. The smoker experiences a satisfactory sensation from such administration. However, smoking may be associated with health hazards not necessarily associated with nicotine administration itself.
As a result, non-smoking methods have been devised to administer nicotine to the body. These include nicotine-containing chewing gums, nicotine-impregnated dermal patches, nicotine inhalers and the like. A variety of patents have disclosed such products.
In U.S. Patent No. 4,692,462 discloses a transdermal drug delivery system having a drug reservoir composed, in part, of an ion exchange resin. The drug reservoir also contains water and therefore has a disadvantageous^ short shelf life.
WO 94/08572 is similar to the above-identified '462 patent but has a nonaqueous component, which increases the shelf life.
U.S Patent 3,901,248 discloses a chewable smoking substitute composition that comprises a chewing gum base and nicotine in combination with certain saliva-insoluble cation exchange resins. When such composition is chewed, nicotine is released in small and reduced amounts into the mouth, within the first few minutes of chewing. The composition is marginally effective in inducing the pleasurable sensation of smoking that is typically desired from those engaged in the therapy that incorporates such chewing gum.
Summary of the Invention
The present invention relates to a nicotine product having a nicotine release rate of not less than 70% over a 10 minute period as well as a process to produce such product Such a product is produced by a process comprising the steps of:
(a) preparing an aqueous solution of an organic polyol;
(b) mixing said aqueous solution of the organic polyol with a cation exchange resin selected from the group consisting of (i) - a methacrylic, weakly acidic type of resin containing carboxylic functional groups (ii) - polystyrene, strongly acidic type of resin contaimng sulfonic functional groups and (iii) - polystyrene, intermediate acidic type of resin containing phosphonic functional groups thereby forming a cation exchange resin mixture having some of its ion exchange sites partially blocked with said polyol;
(c) admixing with said mixture of step (b) an aqueous solution of nicotine to form a nicotinecoated cation exchange resin admixture; and
(d) removing water from said admixture.
The nicotine composition having a nicotine release rate of not less than 70% over a ten minute period results. In accordance with the present invention, a process, product from such process and composition resulting from this process are disclosed. The composition is one that contains nicotine. The nicotine in the composition herein, has a release rate of not less than 70% over a period of 10 minutes. The method by which such release rate is determined is described in more detail in the U.S.P. Official Monograph, Volume 25, pages 1225 and 1226, incorporated herein by reference.
The product produced by the process according to the present invention contains, in addition to the above-disclosed nicotine, a cation exchange resin and an organic polyol.
Any nonionic pharmaceutical grade cationic ion-exchange resin used to bind anionic molecules at the ion exchange sites may be employed in this invention. Examples of such cationic materials are: the those bearing a carboxylic acid group, such as a weakly acidic type of resin containing carboxylic functional groups (these resins are typically derived from polymers or copolymers of methacrylic acid or polymethacrylic acid); the strongly acidic type of resins containing sulfonic functional groups (these resins are typically derived from polymers of styrene or copolymers of styrene and divinylbenzene); or the intermediate acidic type of resins containing phosphonic acid functional groups (these resins are typically derived from polymers of styrene or copolymers of styrene and divinylbenzene).
Cationic ion exchange resins are well know in the art and the present invention encompasses all of these. Representative cation exchange resins of use in accordance with the present invention are disclosed in U.S. Patent No. 3,901,258 incorporated herein by reference. The preferred cation exchange resins are those known in the art as the Amberlite® resins and include, for example, Amberlite® IR-20, Amberlite® IRP-69, Amberlite® IRP-64, Amberlite® IRP-58, Amberlite® IRC-50, Amberlite® IRP-69, etc.
The product in accordance with the present invention also contains as organic polyol. The organic polyol is a non-toxic C2to Cι2 linear or branched hydrocarbon having at least 2 hydroxy groups or a non-toxic C5 to C12 cyclic or heterocyclic hydrocarbon having at least 2 hydroxy groups. The former compounds are illustrated by the polyhydric alcohols such as 1,3- carbohydrates such as glucose, sucrose, etc.
In carrying the process in accordance with the present invention, it is necessary to combine the organic polyol with the cation exchange resin to form a mixture (slurry). Any form of mixing is acceptable. However, it is important that the ratio of cation exchange resin to organic polyol is from about 1:1 to about 5:1. Preferably, the ratio of cation exchange resin to organic polyol is from about 2:1 to about 4:1, most preferably about 2.5:1.
To the mixture (slurry) formed as disclosed above, is admixed an aqueous solution of nicotine. The concentration of nicotine in said aqueous solution of nicotine is from about 5% by weight to about 40% by weight, preferably about 10% to about 30% by weight, most preferably about 15% by weight. However, it should be noted that the weight percent of nicotine in water as used in the present invention is somewhat arbitrary, since water is already present in the process. As set forth herein for this process, such nicotine concentration can be from about 5% to about 40% by weight, but it could also be up to about 50% or higher.
The ratio of cation exchange resin to nicotine is from about 2:1 to about 10:1. Preferably, the ratio of cation exchange resin to nicotine is from about 3:1 to about 6:1, most preferably, about 4:1.
The admixture, which is a water slurry of the cation exchange resin incorporating nicotine and the organic polyol is then dried to remove the water. Such drying can be carried out by any conventional means, i.e., dried over a purge of nitrogen, dried under vacuum, etc.. However, it should be noted that drying the admixture at temperatures in excess of 75 - 80° C cause the disadvantageous loss of nicotine and should be avoided.
The dried admixture is typically sieved to a substantially uniform particle size before being used.
The following Examples demonstrate the process pf the present invention and the compositions resulting from such process. These Examples should not be regarded as limiting the invention in any sense. Nicotine/Resin Process A 1 liter 3-neck, jacketed round bottom flask fitted with external heating/cooling, mechanical agitation and a nitrogen gas inlet is charged with Amberlite® IRP-64 resin (61.0 grams) and a solution of the polyol (24.0 grams) and water (146.4 grams). The mixture is agitated for at least 2 hours at 20 - 25 °C under a nitrogen atmosphere. A solution of nicotine (15.0 grams) and water (36.6 grams) is then added to the mixture and agitation is continued for 1 additional hour.
On completion of the above procedure, the flask is reconfigured for vacuum distillation. Water is distilled from the reaction mixture at a temperature not to exceed 70°C and at ≥ 25" of vacuum. The process is halted when water stops being collected as distillate. At that point, the reaction mixture (the residue remaining in the flask) is a solidified mass. This solid material is transferred to a drying dish and further dried in a vacuum at 50 - 60°C with nitrogen purge. The mixture is considered dry when a Karl Fisher analysis shows the water content in the solid mass to be < 5%.
A number of polyols illustrative of the present invention were individually processed in the above Nicotine/Resin Process. The dried mixtures containing these different polyols were analyzed to determine nicotine concentration and release rate of nicotine according to the procedure set forth in the U.S.P. Official Monograph, Volume 25, pages 1225 and 1226. The results for the illustrative polyols are reported below in the Table 1.
Table 1
While the above results of the above Examples appear unequivocal, i.e., the polyols enhance the release rate of nicotine from the nicotine/resin mixture, in order to establish the precision of this U.S.P. method, a precision study was carried out. It is shown below in Table 2.
Table 2
The data in Table 2 show that the nicotine release rate for the sorbitol-containing sample of 72% is reproducible. Although one sample was measured at 69.3% it is within the normal fluctuation of the method (± 2%). It should be noted that this apparent failure is remedied upon reassay, which is a normal procedure for samples that show a release rate of <70%.
The release rate for the No Polyol is also confirmed by this precision study. It always gives a value of <70%.

Claims

1. A method for preparing a nicotine composition having a nicotine release rate of not less than 70% said method comprising (a) mixing an aqueous solution of an organic polyol with a cation exchange resin selected from the group consisting of (i) - a methacrylic, weakly acidic type of resin containing carboxylic functional groups (iϊ) - polystyrene, strongly acidic type of resin containing sulfonic functional groups and (iii) - polystyrene, intermediate acidic type of resin containing phosphonic functional groups thereby forming a cation exchange resin mixture, said cation exchange resin having some of its ion exchange sites partially blocked with said polyol (b) admixing with said mixture of step (a) an aqueous solution of nicotine to form a nicotinecoated cation exchange resin admixture and (c) removing water from said admixture to produce said nicotine composition having a nicotine release rate of not less than 70%.
2. The method according to Claim 1 wherein the concentration of organic polyol in said aqueous solution of organic polyol is from about 5% by weight to about 60% by weight.
3. The method according to Claim 1 wherein the concentration of nicotine in said aqueous solution of nicotine is from about 5% by weight to about 40% by weight.
4. The method according to Claim 1 wherein the ratio of cation exchange resin to nicotine is from about 2:1 to about 10:1.
5. The method according to Claim 1 wherein the ratio of cation exchange resin to nicotine is from about 3:1 to about 6:1.
6. The method according to Claim 1 wherein the ratio of cation exchange resin to nicotine is about 4:1.
7. The method according to Claim 1 wherein the ratio of cation exchange resin to organic polyol is from about 1:1 to about 5:1.
8. The method according to Claim 1 wherein the ratio of cation exchange resin to organic polyol is from about 2:1 to about 4:1.
9. The method according to Claim 1 wherein the ratio of cation exchange resin to organic polyol is about 2.5:1.
10. The method according to Claim 1 wherein said organic polyol is aC2to C,2 linear or branched hydrocarbon having at least 2 hydroxy groups or a C5 to C]2 cyclic or heterocyclic hydrocarbon having at least 2 hydroxy groups.
11. The method according to Claim 1 wherein said organic polyol is fructose, sucrose or glycerine.
12. A nicotine composition having a nicotine release rate of not less than 70% produced by the process comprising the steps of (a) preparing an aqueous solution of an organic polyol (b) mixing said aqueous solution of the organic polyol with a cation exchange resin selected from the group consisting of (i) - a methacrylic, weakly acidic type of resin containing carboxylic functional groups (ii) - polystyrene, strongly acidic type of resin containing sulfonic functional groups and (iii) - polystyrene, intermediate acidic type of resin containing phosphonic functional groups thereby forming a cation exchange resin mixture having some of its ion exchange sites partially blocked with said polyol (c) admixing with said mixture of step (b) an aqueous solution of nicotine to form a nicotine-coated cation exchange resin admixture and (d) removing water from said admixture to produce said mcotine composition having a nicotine release rate of not less than 70%.
13. The process according to Claim 12 wherein the concentration of organic polyol in said aqueous solution of organic polyol is from about 5% by weight to about 60% by weight.
14. The process according to Claim 12 wherein the concentration of nicotine in said aqueous solution of nicotine is from about 5% by weight to about 40% by weight.
15. The process according to Claim 12 wherein the ratio of cation exchange resin to nicotine is from about 2: 1 to about 10:1.
16. The process according to Claim 12 wherein the ratio of cation exchange resin to nicotine is from about 3: 1 to about 6: 1.
17. The process according to Claim 12 wherein the ratio of cation exchange resin to nicotine is about 4:1.
18. The process according to Claim 12 wherein the ratio of cation exchange resin to organic polyol is from about 1 : 1 to about 5:1.
19. The process according to Claim 12 wherein the ratio of cation exchange resin to organic polyol is from about 2: 1 to about 4:1.
20. The process according to Claim 12 wherein the ratio of cation exchange resin to organic polyol is about 2.5:1.
21. The process according to Claim 12 wherein said organic polyol is aC2to C12 linear or branched hydrocarbon having at least 2 hydroxy groups or a C5 to C12 cyclic or heterocyclic hydrocarbon having at least 2 hydroxy groups.
22. The process according to Claim 12 wherein said organic polyol is fructose, sucrose or glycerine.
23. A nicotine composition having a nicotine release rate of not less than 70% comprising a nicotine coated cation exchange resin selected from the group consisting of (i) - a methacrylic, weakly acidic type of resin containing carboxylic functional groups (ii) - polystyrene, strongly acidic type of resin containing sulfonic functional groups and (iii) - polystyrene, intermediate acidic type of resin containing phosphonic functional groups, said cation exchange resin having some of its ion exchange sites partially blocked by an organic polyol.
24. The composition according to Claim 23 wherein said organic polyol is aC2to Cι2 linear or branched hydrocarbon having at least 2 hydroxy groups or a C5to C12 cyclic or heterocyclic hydrocarbon having at least 2 hydroxy groups.
25. The composition according to Claim 23 wherein said organic polyol is fructose, sucrose or glycerine.
EP03724037A 2002-05-28 2003-04-15 Nicotine-containing, controlled release composition and method Revoked EP1549633B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200331402T SI1549633T1 (en) 2002-05-28 2003-04-15 Nicotine-containing, controlled release composition and method
CY20081101133T CY1108411T1 (en) 2002-05-28 2008-10-13 COMPOSITION OF CONTROLLED NICOTINE CONTROLLED FREEDOM AND METHOD

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US166236 2002-05-28
US10/166,236 US6586449B1 (en) 2002-05-28 2002-05-28 Nicotine-containing, controlled release composition and method
PCT/US2003/011607 WO2003101982A1 (en) 2002-05-28 2003-04-15 Nicotine-containing, controlled release composition and method

Publications (3)

Publication Number Publication Date
EP1549633A1 true EP1549633A1 (en) 2005-07-06
EP1549633A4 EP1549633A4 (en) 2007-04-04
EP1549633B1 EP1549633B1 (en) 2008-07-23

Family

ID=22602397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03724037A Revoked EP1549633B1 (en) 2002-05-28 2003-04-15 Nicotine-containing, controlled release composition and method

Country Status (10)

Country Link
US (2) US6586449B1 (en)
EP (1) EP1549633B1 (en)
AT (1) ATE401885T1 (en)
CY (1) CY1108411T1 (en)
DE (2) DE60322405D1 (en)
DK (1) DK1549633T3 (en)
ES (1) ES2285969T3 (en)
PT (1) PT1549633E (en)
SI (1) SI1549633T1 (en)
WO (1) WO2003101982A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
CA2418135C (en) * 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
ATE359075T1 (en) 2002-12-20 2007-05-15 Niconovum Ab CHEMICALLY AND PHYSICALLY STABLE PARTICLE MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
WO2005053691A2 (en) * 2003-12-02 2005-06-16 Fertin Pharma A/S Nicotine delivery product and method for producing it
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
ATE448786T1 (en) * 2005-06-01 2009-12-15 Fertin Pharma As METHOD FOR PRODUCING A NICOTINE-DELIVERING PRODUCT
KR100699582B1 (en) 2005-07-11 2007-03-23 삼성전기주식회사 Output buffer circuit
JP5694645B2 (en) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ Improved snuff composition
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US9125434B2 (en) 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
EA021392B1 (en) * 2007-10-11 2015-06-30 Филип Моррис Продактс С.А. Smokeless tobacco product
EP2198865B1 (en) 2008-12-19 2011-11-16 Siegfried Ltd. Nicotine-containing product
DK2575759T3 (en) * 2010-05-31 2017-01-23 Fertin Pharma As Formulation comprising nicotine and a cation exchange resin
WO2011150959A1 (en) * 2010-05-31 2011-12-08 Fertin Pharma A/S Formulation comprising nicotine and a cation exchange resin
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
WO2017182084A1 (en) 2016-04-21 2017-10-26 Fertin Pharma A/S Nicotine delivery product, related uses and oral dosage forms, and methods of production
US20220151292A1 (en) * 2020-11-16 2022-05-19 Ncp Nextgen A/S Nicotine pouch composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901248A (en) * 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3845217A (en) * 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US4692462A (en) 1985-03-18 1987-09-08 Menley & James Laboratories, Ltd. Compositions and method of controlling transdermal penetration of topical and systemic agents
AU5354994A (en) * 1992-10-15 1994-05-09 Alza Corporation Delayed onset transdermal delivery device
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system

Also Published As

Publication number Publication date
PT1549633E (en) 2008-10-02
ES2285969T1 (en) 2007-12-01
CY1108411T1 (en) 2014-02-12
ES2285969T3 (en) 2008-12-16
DK1549633T3 (en) 2008-10-06
DE03724037T1 (en) 2007-10-11
ATE401885T1 (en) 2008-08-15
EP1549633A4 (en) 2007-04-04
EP1549633B1 (en) 2008-07-23
DE60322405D1 (en) 2008-09-04
WO2003101982A1 (en) 2003-12-11
US6586449B1 (en) 2003-07-01
US20030224048A1 (en) 2003-12-04
US6828336B2 (en) 2004-12-07
SI1549633T1 (en) 2009-02-28

Similar Documents

Publication Publication Date Title
EP1549633B1 (en) Nicotine-containing, controlled release composition and method
US9801408B2 (en) Nicotine delivery product and method for producing it
US12382984B2 (en) Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
EP1951074B1 (en) Method for producing nicotine with a reduced content of nitrosamines
EP1890698B1 (en) A method of manufacturing a nicotine delivery product
EP3744313B1 (en) Excipients for nicotine-containing therapeutic compositions
WO2012005885A2 (en) Nutraceutical product containing anatabine and yerba maté
WO2007053098A1 (en) A nicotine product with a reduced content of nitrosamines and a carrier
US8728443B2 (en) Formulation comprising nicotine and a cation exchange resin
EP2575759B1 (en) Formulation comprising nicotine and a cation exchange resin
HU199148B (en) Process for producing stable pharmaceutical composition comprising glycerophosphoryl-o-serine and suitable for treating insufficient cerabral activity
CN101355885A (en) Nicotine with low nitrosamine content
EP4609855A1 (en) Method for manufacturing nicotine dry powder for inhalation
EP4516302A1 (en) (s)-2-methyl-5-(1-methyl-2-pyrrolidinyl)pyridine, composition and its use for treating nicotine dependence
US20250073215A1 (en) (s)-2-methyl-5-(1-methyl-2-pyrrolidinyl)pyridine, composition and their use
EP4609856A1 (en) Dry powder inhaler stick containing cough suppressant and dry powder inhaler comprising same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070301

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/465 20060101ALI20070223BHEP

Ipc: C07D 401/04 20060101AFI20031216BHEP

17Q First examination report despatched

Effective date: 20070608

DET De: translation of patent claims
EL Fr: translation of claims filed
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/465 20060101AFI20071205BHEP

Ipc: A61P 25/34 20060101ALI20071205BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60322405

Country of ref document: DE

Date of ref document: 20080904

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20080919

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20080402808

Country of ref document: GR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E002428

Country of ref document: EE

Effective date: 20081014

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2285969

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E004265

Country of ref document: HU

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: FERTIN PHARMA A/S

Effective date: 20090423

NLR1 Nl: opposition has been filed with the epo

Opponent name: FERTIN PHARMA A/S

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: FERTIN PHARMA A/S

Effective date: 20090423

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20160427

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20160426

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20160426

Year of fee payment: 14

Ref country code: FI

Payment date: 20160425

Year of fee payment: 14

Ref country code: IE

Payment date: 20160425

Year of fee payment: 14

Ref country code: CZ

Payment date: 20160505

Year of fee payment: 14

Ref country code: GB

Payment date: 20160427

Year of fee payment: 14

Ref country code: GR

Payment date: 20160428

Year of fee payment: 14

Ref country code: BG

Payment date: 20160422

Year of fee payment: 14

Ref country code: ES

Payment date: 20160426

Year of fee payment: 14

Ref country code: DE

Payment date: 20160426

Year of fee payment: 14

Ref country code: CY

Payment date: 20160511

Year of fee payment: 14

Ref country code: MC

Payment date: 20160426

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20160426

Year of fee payment: 14

Ref country code: HU

Payment date: 20160509

Year of fee payment: 14

Ref country code: DK

Payment date: 20160427

Year of fee payment: 14

Ref country code: PT

Payment date: 20160504

Year of fee payment: 14

Ref country code: SE

Payment date: 20160426

Year of fee payment: 14

Ref country code: IT

Payment date: 20160426

Year of fee payment: 14

Ref country code: SK

Payment date: 20160505

Year of fee payment: 14

Ref country code: TR

Payment date: 20160429

Year of fee payment: 14

Ref country code: AT

Payment date: 20160425

Year of fee payment: 14

Ref country code: EE

Payment date: 20160425

Year of fee payment: 14

Ref country code: SI

Payment date: 20160509

Year of fee payment: 14

Ref country code: BE

Payment date: 20160425

Year of fee payment: 14

Ref country code: RO

Payment date: 20160512

Year of fee payment: 14

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APAY Date of receipt of notice of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA2O

APBA Date of receipt of statement of grounds of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA3O

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60322405

Country of ref document: DE

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E002428

Country of ref document: EE

Effective date: 20170430

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20170430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20170501

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 401885

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170415

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170415

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 4198

Country of ref document: SK

Effective date: 20170415

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20171229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170416

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170501

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170502

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170502

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171103

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170416

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171103

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171016

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170416

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20180111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R064

Ref document number: 60322405

Country of ref document: DE

Ref country code: DE

Ref legal event code: R103

Ref document number: 60322405

Country of ref document: DE

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415

27W Patent revoked

Effective date: 20180302

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180704

REG Reference to a national code

Ref country code: EE

Ref legal event code: MF4A

Ref document number: E002428

Country of ref document: EE

Effective date: 20180619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170416

REG Reference to a national code

Ref country code: SK

Ref legal event code: MC4A

Ref document number: E 4198

Country of ref document: SK

Effective date: 20180302

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 401885

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170415